The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
≥18 years, children under the age of 18 will be excluded due to rarity of disease
Physician's clearance to participate in moderate-vigorous intensity exercise
Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
Parallel
Exercise
Other intervention16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
Attention Control
Other interventionHome-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
Proportion of patients completing the exercise intervention sessions.
The feasibility of the 16-week exercise intervention is defined as the proportion of patients completing the exercise intervention sessions. The analysis population will be the eligible patients who are assigned to the intervention group (N=20). The investigators will estimate the proportion and corresponding 95% exact confidence interval (CI).99 The Investigators expect that the proportion is 70% or higher
Enrollment Rate
The enrollment rate is defined as the proportion of patients who participate in the study among those patients who are approached for the enrollment.
Short Physical Performance Battery (SPPB)-Lower Extremity Function
Short Physical Performance Battery (SPPB), an objective measure of lower-extremity function based on three timed tests of standing balance, walking speed, and chair stand tests, which in older adults is predictive of disability, nursing home admission, and all-cause mortality
Change in 6-minute walk distance
Aerobic fitness will be assessed by the 6-minute walk test (6MWT). The 6MWT has been administered in cancer survivors and has a reliability coefficient of 0.93 when tested in cancer survivors. Participants will be instructed to walk as quickly as possible without running on an indoor pre-measured walkway for 6 minutes
PROMIS- Physical function
Physical function will be assessed using the Patient Reported Outcome Measure Information System (PROMIS) Physical Function-10 scale.
Number of Participants with Treatment Related Adverse Events
NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
Click on the lead sponsor to view all of their trials.
